Drug Profile
Gadofosveset
Alternative Names: Ablavar; AngioMARK; Gadofosveset-trisodium; MS 325; MS 32520; Vasovist; ZK 236018Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer EPIX Pharmaceuticals
- Class Acetates; Amines; Cyclohexanes; Diagnostic agents; Organometallic compounds; Phosphates
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cardiovascular disorders
Most Recent Events
- 20 Nov 2009 The CHMP of the European Medicines Agency makes recommendations to minimise the risk of nephrogenic systemic fibrosis
- 08 Oct 2009 Adverse events data from post-marketing review released by Lantheus Medical Imaging
- 07 Apr 2009 Gadofosveset out-licensed to Lanthus Medical Imaging in the US, Puerto Rico, Canada and Australia ,